+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
BCMA-targeted CAR-T Cell Therapy Market by Product Type (Allogeneic, Autologous), Line of Therapy (Fourth Line and Beyond, Second Line, Third Line), End User, Distribution Channel, Manufacturing Type - Global Forecast 2025-2030- Product Image
BCMA-targeted CAR-T Cell Therapy Market by Product Type (Allogeneic, Autologous), Line of Therapy (Fourth Line and Beyond, Second Line, Third Line), End User, Distribution Channel, Manufacturing Type - Global Forecast 2025-2030- Product Image
Sale

BCMA-targeted CAR-T Cell Therapy Market by Product Type (Allogeneic, Autologous), Line of Therapy (Fourth Line and Beyond, Second Line, Third Line), End User, Distribution Channel, Manufacturing Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6078933
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

BCMA-targeted CAR-T cell therapy is rapidly redefining standards in multiple myeloma, powered by precise genetic engineering, evolving regulatory frameworks, and advanced supply networks. Senior executives navigating this space are seeing marketplace momentum driven by next-generation platforms, targeted innovation partnerships, and resilient supply chains.

Market Snapshot: BCMA-CAR-T Cell Therapy Outlook

The BCMA-targeted CAR-T cell therapy market is experiencing robust expansion, supported by ongoing breakthroughs in cell engineering, manufacturing agility, and clinical adoption. New gene editing techniques and optimized production models are yielding therapies that meet growing demand for rapid, personalized treatments. Regulatory approvals—coupled with active pipelines—are creating additional opportunities for therapy adoption across major healthcare markets. Stakeholder consensus is converging on best practices for quality, safety, and efficacy, creating clearer pathways for global commercialization.

Scope & Segmentation

This report provides a comprehensive exploration of the BCMA-targeted CAR-T cell therapy landscape, structured to deliver actionable intelligence for investors, developers, and strategic leaders.

  • Product Types: Allogeneic and autologous therapies, with distinctions in personalization, scalability, and supply logistics.
  • Lines of Therapy: Analyzes fourth-line and beyond, second-line, and third-line intervention settings, each influencing adoption and development focus.
  • End Users: Academic hospitals, community hospitals, research institutes, and specialty clinics, including outpatient infusion and oncology centers.
  • Distribution Channels: Hospital pharmacies and specialty pharmacies, with tailored dispensing and monitoring workflows.
  • Manufacturing Types: Contract manufacturing services and in-house operations, each with strengths in scale, compliance, or intellectual property (IP) stewardship.
  • Key Regions: Americas (notably United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio), Canada, Mexico, Brazil, Argentina; Europe, Middle East & Africa (spanning UK, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland); and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Technologies: Advanced gene editing, next-gen viral vectors, real-world data analytics, and process automation integrated across supply and clinical functions.
  • Key Companies: Janssen Biotech, Bristol-Myers Squibb, Legend Biotech, bluebird bio, Allogene Therapeutics, Poseida Therapeutics, Atara Biotherapeutics, Precision BioSciences, Cellectis, Sorrento Therapeutics.

Key Takeaways for Decision-Makers

  • Growing convergence between academia, industry, and regulators is refining best practices, accelerating data harmonization and global patient access.
  • Expansion from autologous to allogeneic models is improving scalability and supply flexibility while reducing the time from diagnosis to treatment initiation.
  • Precision medicine initiatives, real-world data, and machine learning insights are enhancing patient stratification and long-term outcome prediction.
  • Strategic manufacturing investments, including regional hubs and automation, are responding directly to supply chain risks and cost pressures.
  • Commercial partnerships and capital allocations are fueling next-generation R&D, as armored, multi-antigen targeting, and dual-construct therapies approach pivotal trial milestones.
  • Integration of digital health and remote monitoring solutions is supporting post-infusion care and improving patient therapy adherence.

Tariff Impact on Supply Chain and Cost Structures

The implementation of new United States tariff measures beginning in 2025 is prompting market participants to reevaluate raw material sourcing and logistics. Increased duties on key inputs, including viral vectors, reagents, and specialized plastics, have accelerated the transition to regional suppliers and localized production hubs. In response, industry leaders are building supply chain redundancy, negotiating volume-based contracts, and adopting advanced inventory strategies to offset cost pressures and mitigate volatility for payers and patients.

Methodology & Data Sources

This analysis adopts a rigorous mixed-methods approach combining secondary research on peer-reviewed data, regulatory filings, patent records, and proprietary technology tracking with structured interviews and quantitative scenario modeling. All findings underwent data triangulation and statistical validation through expert panel review to ensure accuracy and industry relevance.

Why This Report Matters

  • Delivers strategic clarity on emerging therapeutic models, manufacturing innovations, and supply chain adaptation in the BCMA-CAR-T market.
  • Supports decision-making with robust segmentation, technology trend analysis, and actionable recommendations validated by diverse industry leaders.
  • Equips senior executives with early signals of evolving regulatory, clinical, and commercial dynamics impacting global market positioning.

Conclusion

BCMA-targeted CAR-T cell therapy is shaping the future of multiple myeloma treatment, fueled by collaborative innovation and robust supply networks. Organizations that proactively align manufacturing, data-driven clinical strategy, and adaptive market access will be positioned for sustainable leadership in this evolving sector.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging allogeneic BCMA CAR-T therapies aiming to reduce manufacturing time and cost
5.2. Integration of single-dose lymphodepletion regimens to enhance patient tolerability in BCMA CAR-T
5.3. Real-world evidence demonstrating long-term durability and progression-free survival after BCMA CAR-T infusion
5.4. Novel dual-targeting CAR constructs combining BCMA and GPRC5D to overcome antigen escape
5.5. Implementation of point-of-care manufacturing platforms to accelerate BCMA CAR-T therapy delivery
5.6. Development of non-viral gene editing techniques like CRISPR for precise BCMA CAR-T production
5.7. Application of machine learning algorithms to predict patient response and toxicity in BCMA CAR-T treatments
5.8. Expansion of BCMA-targeted CAR-T reimbursement policies improving patient access and coverage
5.9. Exploration of combination therapies pairing BCMA CAR-T with immunomodulatory agents to enhance efficacy
5.10. Investigation of next-generation safety switches to mitigate cytokine release syndrome in BCMA CAR-T
5.11. Advances in preconditioning regimens optimizing immune microenvironment before BCMA CAR-T administration
5.12. Regulatory guidance updates accelerating approval pathways for BCMA-targeted CAR-T products
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. BCMA-targeted CAR-T Cell Therapy Market, by Product Type
8.1. Introduction
8.2. Allogeneic
8.3. Autologous
9. BCMA-targeted CAR-T Cell Therapy Market, by Line Of Therapy
9.1. Introduction
9.2. Fourth Line And Beyond
9.3. Second Line
9.4. Third Line
10. BCMA-targeted CAR-T Cell Therapy Market, by End User
10.1. Introduction
10.2. Hospitals
10.2.1. Academic Hospitals
10.2.2. Community Hospitals
10.3. Research Institutes
10.4. Specialty Clinics
10.4.1. Oncology Centers
10.4.2. Outpatient Clinics
11. BCMA-targeted CAR-T Cell Therapy Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Specialty Pharmacies
12. BCMA-targeted CAR-T Cell Therapy Market, by Manufacturing Type
12.1. Introduction
12.2. Contract Manufacturing
12.3. In-House Manufacturing
13. Americas BCMA-targeted CAR-T Cell Therapy Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa BCMA-targeted CAR-T Cell Therapy Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Janssen Biotech, Inc.
16.3.2. Bristol-Myers Squibb Company
16.3.3. Legend Biotech Corporation
16.3.4. bluebird bio, Inc.
16.3.5. Allogene Therapeutics, Inc.
16.3.6. Poseida Therapeutics, Inc.
16.3.7. Atara Biotherapeutics, Inc.
16.3.8. Precision BioSciences, Inc.
16.3.9. Cellectis S.A.
16.3.10. Sorrento Therapeutics, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BCMA-TARGETED CAR-T CELL THERAPY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BCMA-TARGETED CAR-T CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BCMA-TARGETED CAR-T CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. BCMA-TARGETED CAR-T CELL THERAPY MARKET: RESEARCHAI
FIGURE 26. BCMA-TARGETED CAR-T CELL THERAPY MARKET: RESEARCHSTATISTICS
FIGURE 27. BCMA-TARGETED CAR-T CELL THERAPY MARKET: RESEARCHCONTACTS
FIGURE 28. BCMA-TARGETED CAR-T CELL THERAPY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BCMA-TARGETED CAR-T CELL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY ACADEMIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY ACADEMIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 87. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 88. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 89. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 90. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 91. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 94. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 95. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 96. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 97. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 100. CANADA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 101. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 102. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 103. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 104. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 105. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 108. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 109. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 110. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 111. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 114. MEXICO BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 162. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 173. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 174. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 175. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 176. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 177. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 180. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 181. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 182. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 183. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 186. GERMANY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 187. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 188. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 189. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 190. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 191. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 194. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 195. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 196. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 197. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 200. FRANCE BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 201. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 204. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 215. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 216. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 217. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 218. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 219. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 222. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 223. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 224. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 225. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 228. ITALY BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 229. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 230. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 231. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 232. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 233. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 236. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 237. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 238. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 239. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 242. SPAIN BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 258. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 260. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 272. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 274. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY MANUFACTURING TYPE, 2025-2030 (USD MILLION)
TABLE 285. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 286. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 287. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 288. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 289. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 292. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 293. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 294. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 295. DENMARK BCMA-TARGETED CAR-T CELL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 296. DENMARK BCMA-TARGETED CAR-T CELL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this BCMA-targeted CAR-T Cell Therapy market report include:
  • Janssen Biotech, Inc.
  • Bristol-Myers Squibb Company
  • Legend Biotech Corporation
  • bluebird bio, Inc.
  • Allogene Therapeutics, Inc.
  • Poseida Therapeutics, Inc.
  • Atara Biotherapeutics, Inc.
  • Precision BioSciences, Inc.
  • Cellectis S.A.
  • Sorrento Therapeutics, Inc.

Related Topics

Related Reports

CAR T-cell Therapy - Pipeline Insight, 2025 - Product Image

CAR T-cell Therapy - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025 - Product Image

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025

  • Drug Pipelines
  • 450 Pages
  • Global
From
CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035 - Product Image

CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035

  • Report
  • 598 Pages
  • Global
From
CAR T-Cell Therapy Market Size, Growth, Share, Trends and Forecasts 2025-2033 - Product Image

CAR T-Cell Therapy Market Size, Growth, Share, Trends and Forecasts 2025-2033

  • Report
  • 180 Pages
  • Global
From
Autologous CAR-T Cell Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Autologous CAR-T Cell Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.